3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Marijuana Abuse
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Interventions
Gemcitabine
2
tremelimumab
1
irinotecan sucrosofate
1
durvalumab
1
Taxes
1
Oxaliplatin
1
Medical Marijuana
1
Leucovorin
1
Fluorouracil
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pancreatic Cancer Non-resectable
×
Medical Marijuana
×
Clear all
NCT06605430
2025-07-29
CanPan-C
HealthPartners Institute
Phase 2
Recruiting
64 enrolled